SEC Comment Letter 0000000000-24-012497 to Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc.
Date: Nov. 8, 2024 · CIK: 0001808898 · Accession: 0000000000-24-012497
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282957
Letter
November 8, 2024 Jerel Banks Chief Executive Officer Benitec Biopharma Inc. 2029 Century Park East, Suite 2400 Los Angeles, CA 90067-3010 Re:Benitec Biopharma Inc. Registration Statement on Form S-3 Filed November 1, 2024 File No. 333-282957 Dear Jerel Banks: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Louis Rambo, Esq.
Show Raw Text
November 8, 2024
Jerel Banks
Chief Executive Officer
Benitec Biopharma Inc.
2029 Century Park East, Suite 2400
Los Angeles, CA 90067-3010
Re:Benitec Biopharma Inc.
Registration Statement on Form S-3
Filed November 1, 2024
File No. 333-282957
Dear Jerel Banks:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Louis Rambo, Esq.